These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34448812)

  • 1. Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification.
    van der Werf I; Wojtuszkiewicz A; Meggendorfer M; Hutter S; Baer C; Heymans M; Valk PJM; Kern W; Haferlach C; Janssen JJWM; Ossenkoppele GJ; Cloos J; Haferlach T
    Blood Adv; 2021 Sep; 5(17):3254-3265. PubMed ID: 34448812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia.
    Hou HA; Liu CY; Kuo YY; Chou WC; Tsai CH; Lin CC; Lin LI; Tseng MH; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Huang SY; Ko BS; Hsu SC; Chen CY; Lin CT; Wu SJ; Tsay W; Tien HF
    Oncotarget; 2016 Feb; 7(8):9084-101. PubMed ID: 26812887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results.
    Gardin C; Pautas C; Fournier E; Itzykson R; Lemasle E; Bourhis JH; Adès L; Marolleau JP; Malfuson JV; Gastaud L; Raffoux E; Lambert J; Braun T; Thomas X; Chantepie S; Cluzeau T; de Botton S; Berthon C; Boissel N; Duployez N; Terré C; Peffault de Latour R; Michallet M; Celli-Lebras K; Preudhomme C; Dombret H
    Blood Adv; 2020 May; 4(9):1942-1949. PubMed ID: 32380535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
    Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
    J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and prognostic profile of SRSF2 and related spliceosome mutations in patients with acute myeloid leukemia.
    Jia W; Guo X; Wei Y; Liu J; Can C; Wang R; Yang X; Ji C; Ma D
    Mol Biol Rep; 2023 Aug; 50(8):6601-6610. PubMed ID: 37344641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia.
    Senapati J; Urrutia S; Loghavi S; Short NJ; Issa GC; Maiti A; Abbas HA; Daver NG; Pemmaraju N; Pierce S; Chien KS; Sasaki K; Kadia TM; Hammond DE; Borthakur G; Patel K; Ravandi F; Kantarjian HM; Garcia-Manero G; DiNardo CD
    Blood; 2023 Nov; 142(19):1647-1657. PubMed ID: 37441846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic alternative mRNA splicing signatures and associated splicing factors in acute myeloid leukemia.
    Jin P; Tan Y; Zhang W; Li J; Wang K
    Neoplasia; 2020 Sep; 22(9):447-457. PubMed ID: 32653835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia.
    Khan M; Cortes J; Kadia T; Naqvi K; Brandt M; Pierce S; Patel KP; Borthakur G; Ravandi F; Konopleva M; Kornblau S; Kantarjian H; Bhalla K; DiNardo CD
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28933735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients.
    Tsai CH; Yao CY; Tien FM; Tang JL; Kuo YY; Chiu YC; Lin CC; Tseng MH; Peng YL; Liu MC; Liu CW; Yao M; Lin LI; Chou WC; Chen CY; Hou HA; Tien HF
    EBioMedicine; 2019 Feb; 40():240-250. PubMed ID: 30662003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years.
    Eisfeld AK; Kohlschmidt J; Mims A; Nicolet D; Walker CJ; Blachly JS; Carroll AJ; Papaioannou D; Kolitz JE; Powell BE; Stone RM; de la Chapelle A; Byrd JC; Mrózek K; Bloomfield CD
    Leukemia; 2020 Dec; 34(12):3215-3227. PubMed ID: 32461631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.
    Lo MY; Tsai XC; Lin CC; Tien FM; Kuo YY; Lee WH; Peng YL; Liu MC; Tseng MH; Hsu CA; Chen JC; Lin LI; Sun HI; Chuang YK; Ko BS; Tang JL; Yao M; Chou WC; Hou HA; Tien HF
    Am J Hematol; 2023 May; 98(5):760-769. PubMed ID: 36861732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.
    Gaidzik VI; Teleanu V; Papaemmanuil E; Weber D; Paschka P; Hahn J; Wallrabenstein T; Kolbinger B; Köhne CH; Horst HA; Brossart P; Held G; Kündgen A; Ringhoffer M; Götze K; Rummel M; Gerstung M; Campbell P; Kraus JM; Kestler HA; Thol F; Heuser M; Schlegelberger B; Ganser A; Bullinger L; Schlenk RF; Döhner K; Döhner H
    Leukemia; 2016 Nov; 30(11):2160-2168. PubMed ID: 27137476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigations of the prognostic value of RUNX1 mutation in acute myeloid leukemia patients: Data from a real-world study.
    Wan CL; Huang YH; Huang SM; Xu YL; Tan KW; Yan-Qiu ; Shen XD; Ge SS; Cao HY; Li YY; Liu SB; Qi JJ; Dai HP; Xue SL
    Leuk Res; 2024 Apr; 139():107483. PubMed ID: 38493755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.
    Gaidzik VI; Bullinger L; Schlenk RF; Zimmermann AS; Röck J; Paschka P; Corbacioglu A; Krauter J; Schlegelberger B; Ganser A; Späth D; Kündgen A; Schmidt-Wolf IG; Götze K; Nachbaur D; Pfreundschuh M; Horst HA; Döhner H; Döhner K
    J Clin Oncol; 2011 Apr; 29(10):1364-72. PubMed ID: 21343560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and genomic characterization of patients diagnosed with the provisional entity acute myeloid leukemia with BCR-ABL1, a Swedish population-based study.
    Orsmark-Pietras C; Landberg N; Lorenz F; Uggla B; Höglund M; Lehmann S; Derolf Å; Deneberg S; Antunovic P; Cammenga J; Möllgård L; Wennström L; Lilljebjörn H; Rissler M; Fioretos T; Lazarevic VL
    Genes Chromosomes Cancer; 2021 Jun; 60(6):426-433. PubMed ID: 33433047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Many faces of SF3B1-mutated myeloid neoplasms: concurrent mutational profiles contribute to the diverse clinical and morphologic features.
    Aqil B; Sukhanova M; Behdad A; Jennings L; Lu X; Chen Q; Chen YH; Gao J
    Hum Pathol; 2022 Nov; 129():81-89. PubMed ID: 36087739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.
    Paschka P; Schlenk RF; Gaidzik VI; Herzig JK; Aulitzky T; Bullinger L; Späth D; Teleanu V; Kündgen A; Köhne CH; Brossart P; Held G; Horst HA; Ringhoffer M; Götze K; Nachbaur D; Kindler T; Heuser M; Thol F; Ganser A; Döhner H; Döhner K
    Haematologica; 2015 Mar; 100(3):324-30. PubMed ID: 25596267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation.
    Wang K; Zhou F; Cai X; Chao H; Zhang R; Chen S
    Hematology; 2020 Dec; 25(1):211-218. PubMed ID: 32476595
    [No Abstract]   [Full Text] [Related]  

  • 19. Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia.
    McCarter JGW; Nemirovsky D; Famulare CA; Farnoud N; Mohanty AS; Stone-Molloy ZS; Chervin J; Ball BJ; Epstein-Peterson ZD; Arcila ME; Stonestrom AJ; Dunbar A; Cai SF; Glass JL; Geyer MB; Rampal RK; Berman E; Abdel-Wahab OI; Stein EM; Tallman MS; Levine RL; Goldberg AD; Papaemmanuil E; Zhang Y; Roshal M; Derkach A; Xiao W
    Blood Adv; 2023 Sep; 7(17):5000-5013. PubMed ID: 37142255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.
    Metzeler KH; Becker H; Maharry K; Radmacher MD; Kohlschmidt J; Mrózek K; Nicolet D; Whitman SP; Wu YZ; Schwind S; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
    Blood; 2011 Dec; 118(26):6920-9. PubMed ID: 22031865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.